These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 18068450)

  • 1. Contemporary evaluation of the D'amico risk classification of prostate cancer.
    Hernandez DJ; Nielsen ME; Han M; Partin AW
    Urology; 2007 Nov; 70(5):931-5. PubMed ID: 18068450
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ability of 2 pretreatment risk assessment methods to predict prostate cancer recurrence after radical prostatectomy: data from CaPSURE.
    Mitchell JA; Cooperberg MR; Elkin EP; Lubeck DP; Mehta SS; Kane CJ; Carroll PR
    J Urol; 2005 Apr; 173(4):1126-31. PubMed ID: 15758720
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mayo Clinic validation of the D'amico risk group classification for predicting survival following radical prostatectomy.
    Boorjian SA; Karnes RJ; Rangel LJ; Bergstralh EJ; Blute ML
    J Urol; 2008 Apr; 179(4):1354-60; discussion 1360-1. PubMed ID: 18289596
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 15-Year biochemical relapse free survival in clinical Stage T1-T3 prostate cancer following combined external beam radiotherapy and brachytherapy; Seattle experience.
    Sylvester JE; Grimm PD; Blasko JC; Millar J; Orio PF; Skoglund S; Galbreath RW; Merrick G
    Int J Radiat Oncol Biol Phys; 2007 Jan; 67(1):57-64. PubMed ID: 17084544
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Limited pelvic lymph node dissection does not improve biochemical relapse-free survival at 10 years after radical prostatectomy in patients with low-risk prostate cancer.
    Weight CJ; Reuther AM; Gunn PW; Zippe CR; Dhar NB; Klein EA
    Urology; 2008 Jan; 71(1):141-5. PubMed ID: 18242383
    [TBL] [Abstract][Full Text] [Related]  

  • 6. External validation of University of California, San Francisco, Cancer of the Prostate Risk Assessment score.
    Zhao KH; Hernandez DJ; Han M; Humphreys EB; Mangold LA; Partin AW
    Urology; 2008 Aug; 72(2):396-400. PubMed ID: 18372031
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Subclassification of the D'Amico's high risk group to predict biochemical recurrence after radical prostatectomy].
    Kita Y; Inoue T; Shimizu Y; Kamba T; Yoshimura K; Ogawa O
    Hinyokika Kiyo; 2012 Jul; 58(7):319-24. PubMed ID: 22895126
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reassessment of the risk factors for biochemical recurrence in D'Amico intermediate-risk prostate cancer treated using radical prostatectomy.
    Narita S; Mitsuzuka K; Tsuchiya N; Koie T; Kawamura S; Ohyama C; Tochigi T; Yamaguchi T; Arai Y; Habuchi T;
    Int J Urol; 2015 Nov; 22(11):1029-35. PubMed ID: 26290306
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The specific definition of high risk prostate cancer has minimal impact on biochemical relapse-free survival.
    Nguyen CT; Reuther AM; Stephenson AJ; Klein EA; Jones JS
    J Urol; 2009 Jan; 181(1):75-80. PubMed ID: 19012927
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of biochemical relapse-free survival between primary Gleason score 3 and primary Gleason score 4 for biopsy Gleason score 7 prostate cancer.
    Burdick MJ; Reddy CA; Ulchaker J; Angermeier K; Altman A; Chehade N; Mahadevan A; Kupelian PA; Klein EA; Ciezki JP
    Int J Radiat Oncol Biol Phys; 2009 Apr; 73(5):1439-45. PubMed ID: 18963536
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A retrospective comparison of androgen deprivation (AD) vs. no AD among low-risk and intermediate-risk prostate cancer patients treated with brachytherapy, external beam radiotherapy, or radical prostatectomy.
    Ciezki JP; Klein EA; Angermeier K; Ulchaker J; Chehade N; Altman A; Mahadevan A; Reddy CA
    Int J Radiat Oncol Biol Phys; 2004 Dec; 60(5):1347-50. PubMed ID: 15590163
    [TBL] [Abstract][Full Text] [Related]  

  • 12. After radical retropubic prostatectomy 'insignificant' prostate cancer has a risk of progression similar to low-risk 'significant' cancer.
    Sengupta S; Blute ML; Bagniewski SM; Inman B; Leibovich BC; Slezak JM; Myers RP; Zincke H
    BJU Int; 2008 Jan; 101(2):170-4. PubMed ID: 18173824
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risk-adjusted hazard rates of biochemical recurrence for prostate cancer patients after radical prostatectomy.
    Walz J; Chun FK; Klein EA; Reuther A; Graefen M; Huland H; Karakiewicz PI
    Eur Urol; 2009 Feb; 55(2):412-19. PubMed ID: 19027223
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Contemporary evaluation of the National Comprehensive Cancer Network prostate cancer risk classification system.
    Reese AC; Pierorazio PM; Han M; Partin AW
    Urology; 2012 Nov; 80(5):1075-9. PubMed ID: 22995570
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Conformal radiotherapy for detectable PSA following radical prostatectomy: efficacy and predictive factors of recurrence.
    Delongchamps NB; Zerbib M; Mejean A; Rouach Y; Debre B; Peyromaure M
    Can J Urol; 2009 Oct; 16(5):4813-9. PubMed ID: 19796456
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Oncologic outcomes after radical prostatectomy: French validation of the D'Amico risk group classification].
    Ouzzane A; Koenig P; Ballereau C; Zini L; Ghoneim T; Maladry F; Fantoni JC; Biserte J; Leroy X; Villers A
    Prog Urol; 2010 Dec; 20(13):1206-12. PubMed ID: 21130400
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Is statin use associated with D'Amico risk groups and biochemical recurrence after radical prostatectomy?].
    Misrai V; Do C; Lhez JM; Elman B; Latorzeff I; Portalez D; Grosclaude P
    Prog Urol; 2012 May; 22(5):273-8. PubMed ID: 22515923
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Radical prostatectomy for incidental (stage T1a-T1b) prostate cancer: analysis of predictors for residual disease and biochemical recurrence.
    Capitanio U; Scattoni V; Freschi M; Briganti A; Salonia A; Gallina A; Colombo R; Karakiewicz PI; Rigatti P; Montorsi F
    Eur Urol; 2008 Jul; 54(1):118-25. PubMed ID: 18314255
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Trends in distribution and prognostic significance of Gleason grades on radical retropubic prostatectomy specimens between 1989 and 2001.
    Sengupta S; Slezak JM; Blute ML; Leibovich BC; Sebo TJ; Myers RP; Cheville JC; Bergstralh EJ; Zincke H
    Cancer; 2006 Jun; 106(12):2630-5. PubMed ID: 16703592
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Radical prostatectomy for high-risk prostate cancer: biochemical outcome.
    Kawamorita N; Saito S; Ishidoya S; Ito A; Saito H; Kato M; Arai Y
    Int J Urol; 2009 Sep; 16(9):733-8. PubMed ID: 19674167
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.